We established the efficacy of cotadutide in this patient population, with significantly improved postprandial glucose control and reduced bodyweight versus placebo. Reductions in UACR suggest potential benefits of cotadutide on kidney function, supporting further evaluation in larger, longer-term clinical trials (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: Type 2 Diabetes
Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials
SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk and/or with CKD, without increasing the risk of hypokalemia
Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes
In T2D, a patient’s cardiovascular phenotype can help predict the pattern of future cardiovascular events (Clinical Research in Cardiology)
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
A prespecified sensitivity analysis of protocol-compliant participants showed a significant difference in HbA1c concentration between groups. No new safety signals were identified and there was a low risk of severe hypoglycaemia (The Lancet Diabetes & Endocrinology)
Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes
Add-on pentoxifylline to losartan may have more effective anti-inflammatory and anti-albuminuric roles and therefore may be more applicable in the management of diabetic nephropathy compared with high-dose losartan alone (Diabetes Therapy)
Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial
In this post-hoc analysis of a 4.3-year randomized controlled trial, metformin did not exert a clinically relevant effect on cardiac troponin I and cardiac troponin T levels when compared to placebo. Cardioprotective effects of the drug observed in clinical studies are not reflected by a reduction in these biomarkers of subclinical myocardial injury (Cardiovascular Diabetology)
Type 2 diabetes in adults: management
NICE guideline [NG28]Published: 02 December 2015 Last updated: 31 March 2022 (NICE)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
NICE guideline [NG18]Published: 01 August 2015 Last updated: 31 March 2022 (NICE)
Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes
Analysis from the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58) on the association of baseline HbA1c with cardiovascular and kidney outcomes (Diabetes Care)
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Dapagliflozin contributes to the control of CV risk factors and reduces the risk of microvascular complications (nephropathy and retinopathy) and other non-classical complications of T2DM. The underuse of SGLT2i in general and dapagliflozin in particular, even in patients whose profiles suggest that they could greatly benefit from SGLT2i treatment, indicates that greater effort is needed to translate scientific evidence into actual clinical practice to improve patients’ quality of life (Diabetes Therapy )
Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function
Early intervention with SGLT2i may have renoprotective effects in T2D patients with rapid decline and preserved renal function (Journal of Diabetes Investigation)
Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit
Remission of type 2 diabetes was generally infrequent in routine care settings but may be a reasonable goal for a subset of people who lose a significant amount of weight shortly after diagnosis (Diabetes Care)
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy (Diabetes Care)
Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)
Three-year follow-up of the largest cohort of randomized patients followed to date demonstrates that metabolic/bariatric surgery is more effective and durable than medical/lifestyle intervention in remission of type 2 diabetes, including among individuals with class 1 obesity, for whom surgery is not widely used (Diabetes Care)
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care (Diabetes Therapy)
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
These studies have established finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, as an effective treatment for kidney and CV protection and welcomed addition to the pillars of treatment to slow CKD progression in patients with T2D (Diabetes, Obesity and Metabolism)
Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts
Modeling CKD in T2DM is an active research area, with a trend towards IPS models developed from non-Western data and single data sources, primarily recent outcomes trials of novel renoprotective treatments (Diabetes Therapy)
Relationship Between Muscle Cramps and Diabetic Retinopathy in Patients with Type 2 Diabetes
Muscle cramps occur frequently in diabetes and are correlated with diabetic retinopathy and albumin. Patients with PDR exhibited a higher frequency, severity, and longer duration relative to those with NPDR or without DR (Metabolic Syndrome and Obesity)
Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2h plasma glucose in individuals without diabetes
The serum BA response to a 75g oral glucose load is attenuated in patients with ‘early’ T2D, as is the secretion of FGF-19 and GLP-1, while in individuals without T2D it correlates with 2h plasma glucose levels. These observations support a role for BAs in the regulation of postprandial glucose metabolism (Diabetes, Obesity and Metabolism)
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study
The current study shows that teneligliptin could be a valid option as a fourth OAD for treatment of patients with T2D inadequately controlled with a triple combination of OADs (Diabetes, Obesity and Metabolism)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 62
- Next Page »
Glycosmedia is also available as an App: